000278022 001__ 278022
000278022 005__ 20250430100243.0
000278022 0247_ $$2doi$$a10.1080/17581869.2025.2487413
000278022 0247_ $$2pmid$$apmid:40169386
000278022 0247_ $$2ISSN$$a1758-1869
000278022 0247_ $$2ISSN$$a1758-1877
000278022 037__ $$aDZNE-2025-00532
000278022 041__ $$aEnglish
000278022 082__ $$a610
000278022 1001_ $$00000-0001-5846-7058$$aScuteri, Damiana$$b0
000278022 245__ $$aEfficacy and safety of mAbs anti-CGRP/CGRP R (eptinezumab and erenumab) or atogepant in combination with onabotulinumtoxinA in refractory chronic migraine: a clinical trial protocol.
000278022 260__ $$aLondon$$bTaylor & Francis$$c2025
000278022 3367_ $$2DRIVER$$aarticle
000278022 3367_ $$2DataCite$$aOutput Types/Journal article
000278022 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1745927121_9396
000278022 3367_ $$2BibTeX$$aARTICLE
000278022 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000278022 3367_ $$00$$2EndNote$$aJournal Article
000278022 520__ $$aChronic migraine is a disabling neurovascular disorder that represents the leading cause of years lived with disability in people under 50 with a remarkable social burden due to widespread resistance to the front-line treatments used routinely in current clinical practice. The present study investigates the efficacy and safety of combination therapy using eptinezumab and erenumab, recently approved monoclonal antibodies (mAbs) directed against calcitonin gene-related peptide or its receptor, respectively, or the receptor competitive antagonist atogepant together with botulinum toxin type A in chronic migraine that has proven resistant to front-line treatments for at least 6 weeks. To this aim a retrospective and a prospective phase are designed. Furthermore, a feasible salivary biomarker of migraine is under investigation in the prospective stage of the study. Based on recent expert opinions supporting the switch to easy-to-use small molecule calcitonin gene-related peptide (CGRP)-targeting, i.e. rimegepant or atogepant in unresponsive patients, the present study may offer to clinicians a novel treatment to enhance the therapeutic preventive machinery in chronic migraine.
000278022 536__ $$0G:(DE-HGF)POF4-351$$a351 - Brain Function (POF4-351)$$cPOF4-351$$fPOF IV$$x0
000278022 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000278022 650_7 $$2Other$$aCGRP receptor antagonists
000278022 650_7 $$2Other$$aanti-CGRP monoclonal antibodies
000278022 650_7 $$2Other$$aanti-CGRP-R monoclonal antibodies
000278022 650_7 $$2Other$$aatogepant
000278022 650_7 $$2Other$$achronic migraine
000278022 650_7 $$2Other$$agepants
000278022 650_7 $$2Other$$aonabotulinumtoxinA
000278022 650_7 $$0EC 3.4.24.69$$2NLM Chemicals$$aBotulinum Toxins, Type A
000278022 650_7 $$0I5I8VB78VT$$2NLM Chemicals$$aerenumab
000278022 650_7 $$2NLM Chemicals$$aAntibodies, Monoclonal, Humanized
000278022 650_7 $$2NLM Chemicals$$aCalcitonin Gene-Related Peptide Receptor Antagonists
000278022 650_7 $$08202AY8I7H$$2NLM Chemicals$$aeptinezumab
000278022 650_7 $$0EC 3.4.24.69$$2NLM Chemicals$$aonabotulinum toxin A
000278022 650_7 $$0JHB2QIZ69Z$$2NLM Chemicals$$aCalcitonin Gene-Related Peptide
000278022 650_2 $$2MeSH$$aMigraine Disorders: drug therapy
000278022 650_2 $$2MeSH$$aHumans
000278022 650_2 $$2MeSH$$aBotulinum Toxins, Type A: therapeutic use
000278022 650_2 $$2MeSH$$aBotulinum Toxins, Type A: administration & dosage
000278022 650_2 $$2MeSH$$aAntibodies, Monoclonal, Humanized: therapeutic use
000278022 650_2 $$2MeSH$$aAntibodies, Monoclonal, Humanized: administration & dosage
000278022 650_2 $$2MeSH$$aAntibodies, Monoclonal, Humanized: adverse effects
000278022 650_2 $$2MeSH$$aAntibodies, Monoclonal, Humanized: pharmacology
000278022 650_2 $$2MeSH$$aCalcitonin Gene-Related Peptide Receptor Antagonists: therapeutic use
000278022 650_2 $$2MeSH$$aCalcitonin Gene-Related Peptide Receptor Antagonists: administration & dosage
000278022 650_2 $$2MeSH$$aDrug Therapy, Combination
000278022 650_2 $$2MeSH$$aCalcitonin Gene-Related Peptide: antagonists & inhibitors
000278022 650_2 $$2MeSH$$aProspective Studies
000278022 650_2 $$2MeSH$$aChronic Disease
000278022 650_2 $$2MeSH$$aRetrospective Studies
000278022 650_2 $$2MeSH$$aAdult
000278022 650_2 $$2MeSH$$aTreatment Outcome
000278022 650_2 $$2MeSH$$aMale
000278022 7001_ $$aLawrence, Gary W$$b1
000278022 7001_ $$aIannacchero, Rosario$$b2
000278022 7001_ $$aTrimboli, Michele$$b3
000278022 7001_ $$0P:(DE-2719)2010732$$aNicotera, Pierluigi$$b4$$udzne
000278022 7001_ $$aCorasaniti, Maria T$$b5
000278022 7001_ $$aBagetta, Giacinto$$b6
000278022 773__ $$0PERI:(DE-600)2617136-3$$a10.1080/17581869.2025.2487413$$gVol. 15, no. 4, p. 177 - 181$$n4$$p177 - 181$$tPain management$$v15$$x1758-1869$$y2025
000278022 909CO $$ooai:pub.dzne.de:278022$$pVDB
000278022 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2010732$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000278022 9131_ $$0G:(DE-HGF)POF4-351$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vBrain Function$$x0
000278022 9141_ $$y2025
000278022 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-18
000278022 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-18
000278022 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-18
000278022 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2024-12-18
000278022 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-18
000278022 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPAIN MANAG : 2022$$d2024-12-18
000278022 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-18
000278022 9201_ $$0I:(DE-2719)1013003$$kAG Bano$$lAging and Neurodegeneration$$x0
000278022 980__ $$ajournal
000278022 980__ $$aVDB
000278022 980__ $$aI:(DE-2719)1013003
000278022 980__ $$aUNRESTRICTED